Treatment Characteristics and Real-World Progression-Free Survival in Patients with Unresectable Stage III NSCLC who Received Durvalumab After Chemoradiotherapy: Findings from the PACIFIC-R Study.
暂无分享，去创建一个
N. Girard | R. Fietkau | B. Markman | V. Haakensen | P. Garrido | F. Mornex | J. Bar | F. McDonald | J. Field | M. Garassino | T. Hiltermann | H. Smit | A. Filippi | D. Christoph | Á. Taus | M. Licour | S. Peters | B. Solomon | W. Sawyer | C. Chouaid | A. Sibille | P. Chander | A. Allen | Solange Peters